Targeted Therapies in Lung Cancer Video Perspectives

Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science and Chen-Huang Center for EGFR Mutant Lung Cancers, and senior physician and professor of medicine at Harvard Medical School, spoke with Healio about targeted therapy options for lung cancer, biomarker testing and FDA approvals.

In these videos, Jänne discussed:

• Two studies in lung cancer presented at the ASCO virtual meeting and how the findings will impact clinical practice;
• Recent FDA approvals of target therapies for the treatment of lung cancer;
• The evolution of lung cancer, from a one size fits all approach to a “biomarker-driven disease’;
• Targeted therapies in clinical development for subsets of lung cancer that do not yet have an effective treatment option, such as HER2 and KRAS mutations;
• Resistance biomarkers, their role in choosing a treatment options and how it is a research area “that will continue to evolve”; and
• Why targeted therapy benefits patients with lung cancer.